Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2156-2164

  Liang, Xiang Ming ^a   Otani, Haruhisa ^b,d   Zhou, Qin ^c   Tone, Yoshinori ^d   Fujii, Ryoichi ^d   Mune, Masatoshi ^e   Yukawa, Susumu ^d   Akizawa, Tadao ^f  

^a SHANDONG UNIVERSITY   (China)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Ryoshukai Wakayama Kidney Disease Clinic   (Japan)

^e UNIVERSITY OF NAGASAKI   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyperlipidaemia; Imai rat; Lipoprotein; Oxidative modification; Pitavastatin

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PITAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; GLOMERULOSCLEROSIS; GLOMERULUS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RAT STRAIN; RENAL PROTECTION;

ANIMALS; BLOOD PRESSURE; BLOOD UREA NITROGEN; DEOXYGUANOSINE; ENZYME INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; KIDNEY; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; OXYGEN; QUINOLINES; RATS;

EID: 34547839684     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm168     Document Type: Article

References (46)

1. Moorhead JF, Chan MK, EI-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311
2. Al-Shebeb T, Frohlich J, Magil AB. Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 1988; 33: 498-507
3. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37: 880-891
4. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-374
5. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672
6. Oda H, and Keane WF. Recent advances in statins and the kidney. Kidney Int 1999; 56 [Suppl 71]: S2-S5
7. Keane WF. The role of lipids in renal disease. Future challenges. Kidney Int 2000; 56 [Suppl 75]: S27-31
8. Park JK, Muller DN, Mervaala EM et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58: 1420-1430
9. Moriyama. T, Kawada N, Nagatoya K et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001; 59: 2095-2103
10. Usui H, Shikata K, Matsuda M et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003; 18: 265-272
11. Li C, Yang CW, Park JH et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004; 286: F46-57
12. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF. Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985; 106: 598-604
13. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brepner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-93
14. Kondo S, Yoshizawa N, Wakabayashi K. Natural history of renal lesions in spontaneously hypercholesterolemic (SHC) male rats. Nippon Jinzo Gakkai Shi 1995; 37: 91-99
15. Stahl RA,Thaiss F, Wenzel U, Schoeppe W, Helmehen U. A rat model of progressive chronic glomerular sclerosis: The role of thromboxane inhibition. J Am Soc Nephrol 1992; 2: 1568-1577
16. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerufosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
17. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 56 [Suppl 31]: S29-34
18. Takemura. T, Yoshioka K, Aya N et al. Apolipoproteins and lipoprotein zeceptors in glomeruli in human kidney diseases. Kidney Int 1993; 43: 918-927
19. Ohtani H, Matoba K, Saika Y et al. Glomerular apolipoprotein B deposition in glomerular diseases. Nippon Jinzo Gakkai Shi 1990; 32: 1145-1152
20. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993; 4: 187-194
21. Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998; 54: 848-856
22. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int 2001; 60: 1716-1725
23. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89: 10316-10320
24. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-834
25. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Ling KL, Wolff SP. Low-density lipoprotein is the major carrier of lipid hydroperoxides in plasma. Relevance to determination of total plasma lipid hydroperoxide concentrations. Biochem J 1996; 313: 781-786
26. Reeves PG, Rossow KL, Lindlauf J. Development and testing of the AIN-93 purified diets for rodents: Results on growth, kidney calcification and bone mineralization in rats and mice. J Nutr 1993; 123: 1923-1931
27. Kishi K, Ochiai K, Ohta Y et al. Highly sensitive cholesterol assay with enzymatic cycling applied to measurement of remnant lipoprotein-cholesterol in serum. Clin Chem 2002; 48: 737-741
28. Hotta O, Sugai H, Kitamura H et al. Predictive value of urinary micro-cholesterol (mCHO) levels in patients with progressive glomerular disease. Kidney Int 2004; 66: 2374-2381
29. Maeshima E, Liang XM, Otani H, Mune M, Yukawa S. Effect of environmental changes on oxidative deoxyribonucleic acid (DNA) damage in systemic lupus erythematosus. Arch Environ Health 2002; 57: 425-428
30. Toyokuni S, Tanaka T, Hattori Y et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: Its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76: 365-374
31. Poirier B, Michel O, Bazin R, Bariety J, Chevalier J, Myara I. Conjugated dienes: A critical trait of lipoprotein oxidizability in renal fibrosis. Nephrol Dial Transplant 2001; 16: 1598-1606
32. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67-75
33. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerulax damage in Dahl rats. Kidney Int 1984; 26: 137-143
34. Vyberg M, Nielsen S. Dextran polymer conjugate two-step visualization system for immunohistochemistry. Immunohistochem 1998; 6: 3-10
35. Kim SY, Guijarro C, O'Donnell MP et al. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 1995; 48: 363-371
36. Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996; 22: 147-152
37. Guijarro, C, Kim Y, Schoonover CM et al. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant 1996; 11: 990-996
38. O'Donnell MP, Kasiske BL, Kim Y et al. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-87
39. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human. glomerular mesangial cells. Kidney Int 1993; 44: 503-508
40. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997; 52: 1016-1027
41. Rogler G, Lackner KJ, Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 1995; 76: 114A-116A
42. Negre-Aminou P, van Vliet AK, van Erck M et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-268
43. Arrol S, Mackness MI, Durrington PN. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis 2000; 150: 129-134
44. Sano J, Shirakura. S, Oda S et al. Foam cells generated by a combination of hyperglycemia and hyperlipemia in rats. Pathol Int 2004; 54: 904-913
45. Le Berre L, Herve C, Buzelin F et al. Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. Kidney Int 2005; 68: 2079-2090
46. Short CD, Durrington PN, Mallick NP et al. Serum and urinary high density lipoproteins in glomerular disease with proteinuria. Kidney Int 1986; 29: 1224-1228